The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
Abstract
Summary: Rivaroxaban (Xarelto®) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. The aim was to compare the population pharmacokinetics (PK) and pharmacodynamics (PD) of twice-daily (bid) and once-daily (od) rivaroxaban in patients undergoing total hip replacement (THR). Blood samples were collected from patients enrolled in two phase IIb, dose-ranging studies undertaken to investigate rivaroxaban for thromboprophylaxis after THR. A sparse sampling technique was used and the samples were pooled for PK and PD analysis, which used non-linear mixed effect modelling. Rivaroxaban PK (samples from 758 patients) were well described by an oral, one-compartment model; age and renal function influenced clearance, and body surface area affected volume of distribution. When comparing the same total daily doses, maximum plasma concentrations of rivaroxaban were higher and minimum plasma concentrations were lower with od dosing, compared with bid dosing; however, the 90% intervals overlapped. The area under the plasma concentration–time curve was 18–30% higher in the od than in the bid study. Prothrombin time in seconds (samples from 1181 patients) correlated with rivaroxaban plasma concentrations in a linear fashion in both studies. In conclusion, the PK and PD of rivaroxaban were predictable when given either bid or od. These findings, along with the suggested efficacy and safety of rivaroxaban in the phase II studies, relative to enoxaparin, supported the selection of a convenient, once-daily 10 mg rivaroxaban dose for investigation in phase III studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Bertucci, C., & Domenici, E. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023369673 · Cited by 354
Eriksson, B. I., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Muehlhofer, E., Dierig, C., Misselwitz, F., & Kälebo, P. (2006) · Circulation · doi:10.1161/circulationaha.106.642074 · Cited by 335
Self-citationKubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
Self-citationTURPIE, A. G. G., FISHER, W. D., BAUER, K. A., KWONG, L. M., IRWIN, M. W., KÄLEBO, P., MISSELWITZ, F., & GENT, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01602.x · Cited by 302
Self-citationERIKSSON, B. I., BORRIS, L., DAHL, O. E., HAAS, S., HUISMAN, M. V., KAKKAR, A. K., MISSELWITZ, F., & KÄLEBO, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01657.x · Cited by 302
Self-citation
Cited by
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Self-citationEriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Self-citationUse of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Self-citationKubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., Lufft, V., Wand, D. D., Philipp, T., & Bruck, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03753.x · Cited by 432
Self-citation
Metadata
- Authors
- Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F., Eriksson, B. I., & Mueck, W.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2008
- Volume
- 100
- Issue
- 09
- Pages
- 453-461
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2060578439
- Cited by
- 273
- References
- 19
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. https://app.cochat.ai/papers/10.1160/th07-12-0714
- The paper
- Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F., Eriksson, B. I., & Mueck, W. (2008). Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thrombosis and Haemostasis. https://doi.org/10.1160/th07-12-0714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.